A detailed history of Wells Fargo & Company transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 1,415 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,415
Previous 22,441 93.69%
Holding current value
$0
Previous $948,000 93.99%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$38.96 - $42.75 $819,172 - $898,861
-21,026 Reduced 93.69%
1,415 $57,000
Q1 2024

May 10, 2024

BUY
$40.88 - $43.27 $93,942 - $99,434
2,298 Added 11.41%
22,441 $948,000
Q4 2023

Feb 09, 2024

SELL
$20.27 - $42.44 $600,579 - $1.26 Million
-29,629 Reduced 59.53%
20,143 $854,000
Q3 2023

Nov 13, 2023

SELL
$20.26 - $31.91 $280,742 - $442,176
-13,857 Reduced 21.78%
49,772 $1.09 Million
Q2 2023

Aug 15, 2023

BUY
$23.9 - $35.38 $65,940 - $97,613
2,759 Added 4.53%
63,629 $2.02 Million
Q1 2023

May 12, 2023

BUY
$22.82 - $35.32 $1.03 Million - $1.59 Million
44,954 Added 282.45%
60,870 $1.48 Million
Q4 2022

Feb 13, 2023

BUY
$25.35 - $31.96 $352,491 - $444,403
13,905 Added 691.45%
15,916 $501,000
Q3 2022

Nov 14, 2022

SELL
$25.5 - $41.42 $7,216 - $11,721
-283 Reduced 12.34%
2,011 $57,000
Q2 2022

Aug 12, 2022

SELL
$20.62 - $37.15 $152,464 - $274,687
-7,394 Reduced 76.32%
2,294 $61,000
Q1 2022

May 16, 2022

SELL
$23.5 - $35.38 $324,135 - $487,996
-13,793 Reduced 58.74%
9,688 $339,000
Q4 2021

Feb 14, 2022

SELL
$29.21 - $44.64 $683,163 - $1.04 Million
-23,388 Reduced 49.9%
23,481 $761,000
Q3 2021

Nov 15, 2021

BUY
$21.26 - $38.85 $996,434 - $1.82 Million
46,869 New
46,869 $1.38 Million
Q2 2021

Aug 16, 2021

SELL
$12.56 - $29.69 $12 - $29
-1 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$12.37 - $17.74 $2,956 - $4,239
-239 Reduced 99.58%
1 $0
Q4 2020

Feb 09, 2021

BUY
$9.82 - $18.27 $2,356 - $4,384
240 New
240 $4,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.